Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the overall survival in patients with previously
untreated metastatic pancreatic cancer receiving gemcitabine/nab-paclitaxel plus OGX-427 or
gemcitabine/nab-paclitaxel plus placebo.